Answers are grounded in this paper and cite their sources.
The historical era of the past was not favorable, particularly in terms of managing individuals with type 2 diabetes. During the 1960s, the innovation of a radioimmunoassay for insulin enabled the identification of the unique characteristics of type 1 and type 2 diabetes. Type 2 diabetes was initially treated with sulfonylureas and later phenformin, despite the fact that the mechanisms of action were not fully understood at that time. Subsequently, thiazolidinediones were introduced. Although all medications were linked to weight gain and the actual benefits were uncertain, advancements in basic science elucidated the mechanisms by which glucose is detected and even identified a subset of patients who benefitted from sulfonylureas. The subsequent focus on renin-angiotensin-aldosterone system blockade was considered a significant advancement by many, although the benefits were not as remarkable as anticipated. Various other promising medications emerged and faded over time. Progress was made over the years in understanding the pathology of diabetic kidney disease, which is crucial given that it has become a leading cause of end-stage renal failure. Nevertheless, recent breakthroughs have transformed a bleak scenario and offer hope for the future. Presently, there are medications available that have the potential to significantly benefit individuals with type 2 diabetes. A century after the introduction of insulin, it is indeed a pivotal moment.
No takes yet. Share an insight, caveat, or question.
Samer Younes (2024) studied this question.
Synapse has enriched 7 related papers. Consider them for comparative context: